Reviewer’s report

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Version: 2 Date: 9 August 2012

Reviewer: David Boulton

Reviewer’s report:

This is a clearly written manuscript describing a well-designed and appropriate study needed for the further development of remogliflozin etabonate. The manuscript covers all of the elements needed for a reader to be confident in the design, conduct, bioanalysis and data analysis associated with the study. My only minor comment is to consider the effect of metformin on remogliflozin may be due to metformin’s effects on slowing GI motility which may lead to a decrease in the rate of absorption of RE.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I am an employee/shareholder of Bristol-Myers Squibb Co., which has a compound in development that is also an SGLT2 inhibitor.